ImmuPharma plc (LON:IMM – Get Free Report) fell 5.6% during trading on Friday . The stock traded as low as GBX 1.03 ($0.01) and last traded at GBX 1.15 ($0.01). 845,057 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 911,549 shares. The stock had previously closed at GBX 1.22 ($0.02).
ImmuPharma Stock Performance
The stock has a market cap of £4.79 million, a price-to-earnings ratio of -115.00 and a beta of 1.53. The business has a 50-day simple moving average of GBX 1.39 and a two-hundred day simple moving average of GBX 1.67.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- How to Use the MarketBeat Excel Dividend Calculator
- Constellation Energy: Stock Climbs on Billion-Dollar Contract
- How to Effectively Use the MarketBeat Ratings Screener
- Vistra Stock: Powered for Continued Gains in the New Year
- EV Stocks and How to Profit from Them
- These 3 AI Stocks Are Ready to Lead in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
